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Abstract
The main aim of this work was to evaluate the effect of doxorubicin in complex with C60 fullerene (C60 + Dox) on 
the growth and metastasis of Lewis lung carcinoma in mice and to perform a primary screening of the potential 
mechanisms of C60 + Dox complex action. We found that volume of tumor from mice treated with the C60 + Dox 
complex was 1.4 times less than that in control untreated animals. The number of metastatic foci in lungs of 
animals treated with C60 + Dox complex was two times less than that in control untreated animals. Western blot 
analysis of tumor lysates revealed a significant decrease in the level of heat-shock protein 70 in animals treated 
with C60 + Dox complex. Moreover, the treatment of tumor-bearing mice was accompanied by the increase of 
cytotoxic activity of immune cells. Thus, the potential mechanisms of antitumor effect of C60 + Dox complex include 
both its direct action on tumor cells by inducing cell death and increasing of stress sensitivity and an 
immunomodulating effect. The obtained results provide a scientific basis for further application of C60 + Dox 
nanocomplexes as treatment agents in cancer chemotherapy.
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Background
Suppression of proliferative activity of tumor cells is a 
basic strategy when using traditional chemotherapeutic 
drugs [1]. Doxorubicin (Dox) is the anthracycline anti­
biotic widely used for treatment of cancers of different 
origin [2]. It uses two main mechanisms in cytotoxic ac­
tion towards tumor cells: intercalation into DNA helixes 
followed by inhibition of the DNA synthesis and gener­
ation of free radicals followed by DNA impairment and 
cell membrane damage [3]. However, the antitumor ef­
fect of traditional chemotherapy is always associated 
with numerous negative side effects, in particular, the 
toxicity towards cells of normal organs and tissues. Dox 
causes potent oxidative stress, mitochondrial dysfunc­
tion, and Bcl-2 expression disturbance followed by the 
apoptotic damage in heart tissue. A number of sub­
stances with ability to attenuate the Dox-induced cardio- 
toxicity have been developed nowadays in order to 
improve the outcome of the long-term treatment with
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Dox [4]. In that regard, C60 fullerene is a promising car­
bon nanostructure that is characterized by unique phys­
ical and chemical properties [5] and biological activity 
both in vitro and in vivo [6].
It was established that pristine C60 fullerenes at low 
concentrations are nontoxic [7, 8] and they are able to 
penetrate through the cytoplasmic membrane of treated 
cells [9]. One of the biologically most relevant features 
of C60 fullerene is its antioxidant effect [10]. Our previ­
ous results also revealed antioxidant properties of pris­
tine C60 fullerene [11].
C60 fullerene and its derivatives possess potent antican­
cer activity [12]. It has been reported that C60 fullerene 
nanocrystal induces certain hallmarks of autophagy in 
cancer cells [13]. The tumor inhibitory effect of fullerenes 
is accompanied by the immunomodulatory activity [14].
It is important to emphasize that chemical modifica­
tion of the surface of C60 molecule for improvement of 
its water solubility often leads to changes in its physical 
and chemical properties and to a decrease in specific 
biological effects. Thus, utilization of pristine C60 fuller- 
ene would be more desirable. In our previous study [15], 
we showed that the water-soluble pristine C60 fullerene
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directly suppresses growth of transplanted malignant 
tumor. Chen et al. [16] reported that antitumor effect of 
pristine and functionalized C60 fullerene might be asso­
ciated with modulation of the oxidative stress and the 
anti-angiogenic and immunostimulatory activity. Injac et 
al. [17] demonstrated the ability of fullerenol to decrease 
the acute Dox pulmotoxicity in rats with malignant neo­
plasm through inhibition of oxidative stress. In our pre­
vious study [18], it was shown that the combination of 
Dox with C60 fullerene resulted in increase of thera­
peutic efficacy of the treatment. Taking into account 
these data, we also suggested [19, 20] that Dox 
immobilization on C60 fullerene (C60 + Dox complex for­
mation) can reduce negative side effects of this drug to­
wards normal cells as well as enhance its ability to enter 
target tumor cells.
The main goal of this work was to (1) evaluate the ef­
fect of C60 + Dox complex on growth and metastasis of 
Lewis lung carcinoma (LLC) and (2) perform primary 
screening of the potential mechanisms of C60 + Dox 
action.
Methods
Material Preparation and Characterization
The highly stable aqueous colloid solution of purified 
C60 fullerene (C60FAS; concentration 0.15 mg/ml) was 
prepared as reviewed in [21, 22]. The method is based 
on the technology of transferring C60 molecules from 
toluene to an aqueous phase with the help of ultrasonic 
treatment.
The atomic force microscopy (AFM) data [21- 23] 
confirm randomly arranged individual C60 molecules 
with a diameter of ~0.7 nm and their bulk sphere-like 
aggregates with a height of 2-100 nm in C60FAS.
Dox (“Doxorubicin-TEVA”, Pharmachemie B.V.) was 
dissolved in saline at initial concentration 0.15 mg/ml 
and used in all experiments. It was immobilized on the 
С60 fullerene according to the following protocol: 
C60FAS (0.15 mg/ml) and Dox (0.15 mg/ml) were mixed 
in 1:2 volume ratio, and the resulting mixture was 
treated for 20 min in the ultrasonic disperser. After 
that, it was subjected to 12-h magnetic stirring at 
room temperature. Pronounced hypochromic effect 
observed in spectrophotometric experiment and AFM 
data clearly indicate a formation of stable C60 + Dox 
complex [19, 20].
Animals
The male C57Bl/6 mice (20-21 g weight) were kept at 
298 ± 1 K on a standard diet in the vivarium of R.E. 
Kavetsky Institute of Experimental Pathology, Oncology 
and Radiobiology, NAS of Ukraine (Kyiv). All experi­
ments were conducted in accordance with the inter­
national principles of the European Convention for
protection of vertebrate animals under the control of 
Bio-Ethics Committee of that institution.
Tumor Model, Treatment Regimens, and Study Design
LLC was used as an experimental model. LLC cell line 
was obtained from the cell line bank of the R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology, NAS of Ukraine (Kyiv). Tumor cells 
(5 x 105 in the volume of 100 pl) were transplanted 
intramuscularly into the mouse limb. After transplant­
ation of tumor cells, the experimental animals were 
randomized by weight and distributed in four groups 
with ten animals per group:
Group 1 (C60 fullerene injection). C60FAS was used in 
1.5 mg/kg dose (0.2 ml) injected intraperitoneally to 
mice with transplanted tumor once per day for 5 days 
with a day interval [15].
Group 2 (Dox injection). Dox was used in 1.5-mg/kg 
dose (0.2 ml) injected intraperitoneally to mice with 
transplanted tumor once per day for 5 days with a day 
interval [24].
Group 3 (C60 + Dox complex injection). C60 + Dox 
mixture was used in 1.5-mg/kg dose (0.2 ml) injected 
intraperitoneally to mice with transplanted tumor once 
per day for 5 days with a day interval.
Control. The mice with transplanted tumor were 
injected with saline (0.2 ml) once per day for 5 days 
with a day interval.
Intact animals were used in order to investigate im­
munological indices (cytotoxic activity of the peritoneal 
macrophages and mononuclear splenic leucocytes).
The injections of C60 fullerene, Dox, or C60 + Dox 
complex were started on the 2nd day after tumor cell 
transplantation. The protocol of injecting C60 fullerenes 
was based on the fact that C60 fullerenes administered 
intraperitoneally to rats (500 mg/kg) were subjected to 
clearance from the organism within 2-4 days [25]. The 
C60 fullerene dose applied in our experiments was sig­
nificantly lower than the LD50 value determined for C60 
fullerene which, after oral administration to mice, was 
equivalent to 600 mg/kg of body weight [25].
The kinetics of tumor growth was evaluated as de­
scribed [15] by linear dimensions of tumor measured 
every third day with the use of calipers starting from the 
9th day after tumor cell inoculation. The euthanasia of 
experimental animals was performed at the end of the 
experiment (22nd day), and the number and size of me- 
tastases in animal lungs were monitored.
Anticancer effect was also characterized by growth 
inhibition index, GII, calculated by the formula 
GII = (V - Vexp)/V  x 100 %, where V  and Vexp are the 
average volumes of tumor of control and experimental
Prylutska et al. Nanoscale Research Letters (2015) 10:499 Page 3 of 7
Fig. 1 Th e  effect o f treatment w ith  C60 fu l l erene, Dox, and C60 +  Dox complex on tum o r vo l ume in LLC-bearing mice; the differences are statistica l ly 
valid compared to the control (t test; *p <  0.05, **p <  0.01)
animals, respectively; V = 1/2 -(m^)3, where a and b are 
the length and width (in millimeters) of the tumor site, re­
spectively [15].
M TT Assay
To analyze cytotoxic activity of the peritoneal macro­
phages and mononuclear splenic leukocytes, the modi­
fied MTT assay was used as described [26]. Cytotoxic 
activity of the studied samples was calculated using the 
formula Cytotoxicity index = (1-e/ec) x 100 %, where ec 
and e are the extinctions of control and test sample, re­
spectively. Measurement of extinction was performed on 
a digital spectrophotometer (pQuant, BioTEK, USA) at 
the wavelength of 540 nm.
The investigation of cytotoxic activity of immunocytes 
was performed on the 22nd day after tumor cell trans­
plantation. Suspension of tumor cells was prepared from 
tissue homogenates. Mononuclear splenic leukocytes 
were obtained from splenocyte suspension by centrifuga­
tion (1500 rpm, 40 min) in Ficoll-Hypaque density gradi­
ent (p = 1.077). Peritoneal macrophages were isolated 
without preliminary stimulation. Mice were sacrificed, and 
peritoneal macrophages were harvested using phosphate- 
buffered saline containing 100 U/ml of heparin. Cells were 
centrifuged at 300xg for 5 min at 4 °C, washed twice with 
serum-free DMEM, and re-suspended in DMEM contain­
ing 10 % FCS and 40 pg/ml gentamicin.
To perform cytotoxic assay, LLC cells were placed in 96- 
well plates (3 x 105 cells/well), and mononuclear splenic 
leukocytes or peritoneal macrophages were added at 20:1 
ratio. Cells were incubated in a RPMI-1640 medium 
supplemented with gentamicin sulfate (100 pg/ml) and 
maintained at 37 °C for 18 h in 5 % CO2 atmosphere. After 
incubation, MTT (Sigma) was added to a final
concentration of 0.5 mg/ml followed by culturing for 3 h. 
After culturing, cells were centrifuged at 4000 rpm 
(1600xg) for 10 min. Culture medium was removed, and 
blue formazan crystals were dissolved in 100 pl DMSO. 
Optical density was determined at 570 nm.
Western Blot Analysis
The tumors were surgically removed, and cell lysates 
were prepared by EDTA extraction. After removal of 
unlysed cell remnants and nuclei by centrifugation in 
the Eppendorf micro-centrifuge (5 min, 10,000 rpm, 
10,200xg); protein concentration was determined by 
standard method, as described [27]; and 10 pg of equal 
amounts of protein was loaded into 15 % polyacrylamide 
gel. Proteins were resolved and transferred to Immobilon- 
P membrane (Millipore, Billerica, MA) using semi-dry 
transfer (Bio-Rad, Hercules, CA). After incubating the 
membrane in the blocking buffer, the membrane was in­
cubated with heat-shock protein 70 (HSP70) monoclonal 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). 
For a loading control, the levels of expression of the |3- 
actin were detected in each sample using mouse |3-actin 
monoclonal antibodies (Sigma). Immunoreactive bands 
were visualized by chemiluminescence using horseradish
Table 1 Tum or growth inhibition index (GII, %) for each 
experimental group on the 9th, 13th, 18th, and 22nd day after 
tumor inoculation
Anim al g roup Day after tu m o r cell 
transplantation
9 13 18 22
Group 1 (C60 fullerene injection), n =  10 26 20 22 12
Group 2 (Dox injection), n =  10 13 22 21 13
Group 3 (C60 +  Dox injection), n =  10 24 22 29 29
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Table 2 The effect of C60 fullerene and Dox used alone and in C60 + Dox complex on the LLC metastases
A n im a lg ro u p  Th e  num ber o f tu m o r nodules in lungs
N od u le  diam eter (mm) Tota l
num ber
<0.5 0.5 1 2 3 4 5
Contro l, n =  10 12 9 33 25 3 7 11 100
Group 1(C60 fu lle rene injection), n =  10 20 22 23 8 9 1 1 84
Group 2(Dox injection), n =  10 14 5 25 16 7 1 1 69
Group 3(C60 +  Dox injection), n =  10 16 10 6 16 - - - 48
peroxidase-conjugated IgG antibodies and ECL Kit 
(Amersham, Uppsala, Sweden) according to the instruc­
tions of the manufacturer.
Statistical Analysis
For statistical analysis of the obtained results, standard 
variation data within a group was calculated together 
with a statistical reliability of differences between two 
groups of data assessed by Student’s t test. The level of 
significance was set to p  < 0.05.
Results and Discussion
Treatment with C60 + Dox Complex Results in the 
Inhibition of Tumor Growth and Metastasis and Increases 
Stress Sensitivity of Tumor Cells In Vivo
Experimental animals tolerated the treatment well and 
exhibited normal behavior, as determined by the activity 
level and grooming behavior throughout the study.
LLC was characterized by a significant growth of its size 
(volume) from the 9th to the 22nd day of the experiment 
(Fig. 1). One can see that all applied treatments (C60 ful­
lerene, Dox, and C60 + Dox complex) caused a decrease 
(comparing to control, i.e., untreated mice) of tumor vol­
ume. Tumor volume in animals of group 1 (C60 fullerene 
injection) and group 2 (Dox injection) differed slightly. 
The volume of tumor from mice treated with the C60 + 
Dox complex was significantly lower than that in control 
untreated animals, viz. by 1.4 times.
The effect of C60 fullerene and Dox used alone and in 
C60 + Dox complex on tumor growth was evaluated by 
the GII value presented in Table 1.
Thus, on the 13th day after cancer cell inoculation, 
tumor volume in mice treated with Dox and C60 + Dox
complex was 22 % less than that in the untreated ani­
mals. There was no inhibition of tumor growth in mice 
treated with C60 fullerene alone. On the 18th day after 
cancer cell transplantation, we observed the most 
expressed retardation of tumor growth in animals treated 
with C60 + Dox complex, and the GII value in mice of that 
group was 29 %. At that time point, the tumor volume in 
mice treated with C60 fullerene and Dox was ~22 % less 
than that in the untreated animals. On the 22nd day after 
cancer cell inoculation, the GII value in mice treated with 
C60 fullerene and Dox was decreased by ~13 %, but it did 
not change in mice treated with C60 + Dox complex.
The treatment of tumor-bearing mice with C60 fuller- 
ene, Dox, and C60 + Dox complex caused an inhibition 
of metastasis of the experimental tumor (Table 2). The 
number of the metastatic foci in lungs of animals of the 
group treated with C60 + Dox complex was two times 
less than that in the untreated animals and 1.4 times less 
than that in mice treated with Dox alone. It should be 
noted that the metastatic foci in mice treated with C60 
fullerene, Dox, and its complex were characterized by 
different sizes. While in the control group, large meta­
static foci that infiltrated into the lung parenchyma were 
observed; the metastatic foci were much smaller and 
solitary in mice treated with Dox and C60 + Dox com­
plex. In mice treated with C60 + Dox complex, the meta­
static foci with the diameter of >3 mm were absent. 
Since only tumor growth beyond the size of 1-2 mm 
is angiogenesis-dependent [28], we suggested that the 
small-sized metastatic focus (<1 mm in diameter) is 
in a state of dormancy. Therefore, one can suppose 
that C60 + Dox complex exerts a negative effect to­
wards tumor angiogenesis.
p-actin
1 2  3 4
Fig. 2 Th e  effect o f treatm ent w ith  C60 +  D ox com plex on the le v e lo f H SP70  in tu m o r tissu e  o f anim als w ith  LLC (representative W este rn blot). 
1 and 2— c o n tro la n im a ls (untreated); 3 and 4 — C60 +  Dox-treated anim als
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F ig .3  Th e  effect o f treatm ent w ith  C60 fulle rene, Dox, and C60 +  Dox com plex on the cytotoxic activity o f peritonealm acrophages tow ards 
autologic tu m o r cells in LLC-bearing mice; *the  d ifferences are statistica lly valid compared to the control (t test; p <  0.05); **the  differences are 
statistica lly valid compared to the intact animals (t test; p <  0.05)
It is known that HSP70 is aberrantly expressed in 
cancer cells of different origins. The survival of these 
cells strongly depends upon HSPs due to their role not 
only in protein refolding and degradation but also in 
preventing apoptosis [29]. Elevated expression of 
HSP70 is associated with poor response of tumor cells 
to chemotherapy, and inhibition of its expression was 
shown to be an effective strategy against cancer [30]. 
Therefore, we have measured the level of HSP70 in 
tumor tissue of animals treated with Dox and C60 + 
Dox complex. Western blot analysis of tumor cell ly­
sates revealed a significant decrease in HSP70 level only 
in animals treated with C60 + Dox complex (Fig. 2). The 
level of HSP70 in tumor lysates from mice treated with 
Dox alone did not differ from that in the untreated 
tumor-bearing mice.
The obtained results clearly demonstrate that the anti­
cancer activity of Dox is not only well preserved in its 
complex with C60 fullerene, but it is even enhanced after 
formation of such complex.
C60 + Dox Complex Modulates Immunological Reactivity 
of Tumor-Bearing Mice
С60 fullerene and its derivatives were shown to possess 
the immunomodulating properties [14]. Thus, we sup­
posed that the immunomodulating effect of С60 + Dox 
complex can be involved in its antitumor action. To test­
ify this hypothesis, the cytotoxic activity of mononuclear 
splenic leukocytes and macrophages towards autologic 
tumor cells was evaluated in tumor-bearing mice treated 
with the С60 + Dox complex.
Fig. 4 Th e  effect o f treatm ent w ith  C60 fulle rene, Dox, and C60 +  Dox com plex on the cytotoxic activity o f m ononuclear sp lenic leukocytes 
tow a rd s auto log ic  tu m o r ce lls in LLC -bearing mice; *th e  d iffe rences are sta tistic a lly  valid compared to the  control and intact animals 
(t test; p <  0.05)
Prylutska et al. Nanoscale Research Letters (2015) 10:499 Page 6 of 7
Growth of experimental tumor was associated with a 
decrease of macrophage cytotoxicity towards autologic 
tumor cells in vitro (Fig. 3).
Treatment with Dox as well as with С60 fullerene used 
alone and in С60 + Dox complex resulted in increased 
cytotoxic activity of the peritoneal macrophages of 
tumor-bearing mice. Cytotoxic indices of the peritoneal 
phagocytes in treated animals were comparable with 
those in the intact mice.
Cytotoxic activity of splenic mononuclear leukocytes 
in tumor-bearing mice did not differ from that in the in­
tact animals (Fig. 4).
Treatment with Dox resulted in an increase of spleno- 
cyte cytotoxicity. A significant individual variability of 
cytotoxic indices in animals from this group should be 
noted. Cytotoxicity indices of the mononuclear splenic 
leukocytes in animals treated with С60 fullerene used 
alone and in С60 + Dox complex were significantly 
higher than those in the untreated tumor-bearing mice. 
The most positive effect was observed in animals receiv­
ing С60 + Dox complex. Cytotoxic activity of splenic 
mononuclear cells towards autologic tumor cells is sub­
stantially mediated by splenic NK cells [31]. Turabekova 
M et al. reported that С60 fullerene might be recognized 
by Toll-like receptors (TLRs) [32]. TLR-dependent 
stimulatory effect of the preparation and an increased 
stress sensitivity of LLC cells associated with a decreased 
HSP70 expression might be potential reasons of in­
creased cytotoxicity of splenic mononuclear cells in ani­
mals receiving С60 + Dox complex.
Conclusions
The results of performed experiments demonstrated that 
treatment of mice bearing LLC with C60 + Dox nano­
complexes is associated with a significant antitumor effect, 
namely, (1) the volume of tumor of mice treated with C60 
+ Dox complex was 1.4 times smaller than that in the con­
trol untreated animals; (2) the number of metastatic foci 
in lungs of animals of the group treated with C60 + Dox 
complex was two times smaller than that in control un­
treated animals; (3) there were no metastatic foci with 
diameter >3 mm in mice treated with C60 + Dox complex. 
Western blot analysis of tumor cell lysates of animals 
treated with C60 + Dox complex revealed a significant de­
crease in the HSP70 level. The MTT assay showed that 
C60 + Dox complex modulates immunological reactivity of 
tumor-bearing mice. The potential mechanisms of C60 + 
Dox complex antitumor effect are likely to be based on its 
direct action on tumor cells with inducing cell death as 
well as an increasing of stress sensitivity and immunomo- 
dulating effect. Thus, the C60 + Dox nanocomplexes might 
be proposed as new pharmacological agents that are ef­
fectively killing tumor cells and simultaneously stimulat­
ing immune responses in tumor-bearing mice.
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